

Bondronat

1. Bondronat. Monographie du médicament du 17 février 2004.
2. Solimando DA. Overview of hypercalcemia of malignancy. *Am J Health Syst Pharm* 2001;58(Suppl 3):S4-S7.
3. Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergstrom B. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. *Support Care Cancer* 2003;11:539-47.
4. Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized Phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. *J Clin Oncol* 1996;14(1):268-76.
5. Ralston SH, Thiebaud D, Herrmann, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. *Br J Can* 1997;75(2):295-300.
6. Burckhardt P. Ibandronate in oncology. *Cancer* 1997;80(suppl 8):1696-8.
7. Oleffe V, Dumon JC, Body JJ. Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: effects of bisphosphonate therapy and surgery. *J Surg Oncol* 1996;63:125-9.
8. Dooley M, Balfour JA. Ibandronate. *Drugs* 1999;57(1):101-8.
9. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcemia of malignancy. *Drug Safety* 1999;21(5):389-406.
10. Davidson TG. Conventional treatment of hypercalcemia of malignancy. *Am J Health Syst Pharm* 2001;58(Suppl 3):S8-S15.
11. Woloschuk DMM, Watral W. Hypercalcemia (Chapter 86). In: Gray J (ed). *Therapeutic Choices* (4th ed), Canadian Pharmacists Association, Ottawa, ON, 2003.
12. Bondronat. Discussion scientifique. Agence européenne pour l'évaluation des médicaments. 19 novembre 2004. Disponible à l'adresse suivante : <http://www.emea.eu.int/humandocs/Humans/EPAR/bondronat/bondronat.htm>
13. British Columbia Cancer Agency. Protocol Summary of the Guidelines for the Diagnosis and Management of Malignancy Related Hypercalcemia. April 1, 2003. Available at: <http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/SupportiveCare/SCHYPCAL.htm>.
14. Action Cancer Ontario. Formulaire. Mai 2004. Acide zolendronique. Pamidronate. Clodronate. Disponible à l'adresse suivante : http://www.cancercare.on.ca/access_144.htm.